Siemens Healthineers’s CFO on Earnings, Guidance, Covid Tests

The transcript discusses the company's decision to raise its guidance for comparable sales, largely due to increased demand for antigen testing. It highlights strong growth in diagnostics and imaging, with a focus on recovery in the US and European markets. The conversation also touches on the company's involvement in COVID test kits and potential opportunities in emerging markets.

What is the expected revenue for antigen tests as mentioned in the text?

What regions are mentioned as having strong demand throughout the pandemic?